Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V0034 CR 01B in uremic xerosis
NCT01084148Phase 3Completed
- Sponsor
- Orphagen Therapeutics
- Start
- Jan 2007
- Primary completion
- Jan 2009
01
Overview
Phase 3, randomised, double-blind trial in uremic xerosis comparing V0034 CR 01B with Vehicle (2 arms). Primary endpoint: Treatment Response of Xerosis at 28 days. Started Jan 2007; status: completed.
02
Drugs
Dexeryl
03
Conditions
uremic xerosis
Beyond the preview
Go deeper on NCT01084148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084148.